Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

计划入组 24 人 · 首次发布于 2018 年 4 月 13 日

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

计划入组 14 人 · 首次发布于 2014 年 10 月 28 日

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

计划入组 43 人 · 首次发布于 2018 年 8 月 29 日

NUCC-0227383

EBV-specific TCR-T cells (nasopharyngeal carcinoma/ metastatic head and neck carcinoma)

Head and Neck Cancer(Diakonos)

Danish Head And Neck Cancer Group

CELL AND GENE THERAPY CATAPULT

United Kingdom

INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE

India

Adlai Nortye's Buparlisib Poised to Potentially Be First PI3K Inhibitor for Head and Neck Cancer

Eseba-vec Plus Pembrolizumab Shows Promise in HPV16-Positive Head and Neck Cancer

Ultra-Low-Dose Immunotherapy Combination Demonstrates Superior Survival in Metastatic Head and Neck Cancer